These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 31995666)

  • 1. CRISPR-Cas systems in oral microbiome: From immune defense to physiological regulation.
    Gong T; Zeng J; Tang B; Zhou X; Li Y
    Mol Oral Microbiol; 2020 Apr; 35(2):41-48. PubMed ID: 31995666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppressing the CRISPR/Cas adaptive immune system in bacterial infections.
    Gholizadeh P; Aghazadeh M; Asgharzadeh M; Kafil HS
    Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2043-2051. PubMed ID: 28601970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CRISPR-Cas Mechanism for Adaptive Immunity and Alternate Bacterial Functions Fuels Diverse Biotechnologies.
    Newsom S; Parameshwaran HP; Martin L; Rajan R
    Front Cell Infect Microbiol; 2020; 10():619763. PubMed ID: 33585286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CRISPR proteins targeting the CRISPR-Cas system enrich the toolkit for genetic engineering.
    Liu Q; Zhang H; Huang X
    FEBS J; 2020 Feb; 287(4):626-644. PubMed ID: 31730297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR-Cas: Complex Functional Networks and Multiple Roles beyond Adaptive Immunity.
    Faure G; Makarova KS; Koonin EV
    J Mol Biol; 2019 Jan; 431(1):3-20. PubMed ID: 30193985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. History of CRISPR-Cas from Encounter with a Mysterious Repeated Sequence to Genome Editing Technology.
    Ishino Y; Krupovic M; Forterre P
    J Bacteriol; 2018 Apr; 200(7):. PubMed ID: 29358495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization and applications of Type I CRISPR-Cas systems.
    Hidalgo-Cantabrana C; Barrangou R
    Biochem Soc Trans; 2020 Feb; 48(1):15-23. PubMed ID: 31922192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR-Cas systems: beyond adaptive immunity.
    Westra ER; Buckling A; Fineran PC
    Nat Rev Microbiol; 2014 May; 12(5):317-26. PubMed ID: 24704746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diverse Mechanisms of CRISPR-Cas9 Inhibition by Type II Anti-CRISPR Proteins.
    Hwang S; Maxwell KL
    J Mol Biol; 2023 Apr; 435(7):168041. PubMed ID: 36893938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptation in CRISPR-Cas Systems.
    Sternberg SH; Richter H; Charpentier E; Qimron U
    Mol Cell; 2016 Mar; 61(6):797-808. PubMed ID: 26949040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Analysis of Porphyromonas gingivalis W83 CRISPR-Cas Systems.
    Burmistrz M; Dudek B; Staniec D; Rodriguez Martinez JI; Bochtler M; Potempa J; Pyrc K
    J Bacteriol; 2015 Aug; 197(16):2631-41. PubMed ID: 26013482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survey of clustered regularly interspaced short palindromic repeats and their associated Cas proteins (CRISPR/Cas) systems in multiple sequenced strains of Klebsiella pneumoniae.
    Ostria-Hernández ML; Sánchez-Vallejo CJ; Ibarra JA; Castro-Escarpulli G
    BMC Res Notes; 2015 Aug; 8():332. PubMed ID: 26238567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization and Repurposing of Type I and Type II CRISPR-Cas Systems in Bacteria.
    Hidalgo-Cantabrana C; Goh YJ; Barrangou R
    J Mol Biol; 2019 Jan; 431(1):21-33. PubMed ID: 30261168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meet the Anti-CRISPRs: Widespread Protein Inhibitors of CRISPR-Cas Systems.
    Hwang S; Maxwell KL
    CRISPR J; 2019 Feb; 2(1):23-30. PubMed ID: 31021234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cas1 and Cas2 From the Type II-C CRISPR-Cas System of
    He Y; Wang M; Liu M; Huang L; Liu C; Zhang X; Yi H; Cheng A; Zhu D; Yang Q; Wu Y; Zhao X; Chen S; Jia R; Zhang S; Liu Y; Yu Y; Zhang L
    Front Cell Infect Microbiol; 2018; 8():195. PubMed ID: 29951376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Why so rare if so essentiel: the determinants of the sparse distribution of CRISPR-Cas systems in bacterial genomes].
    Bernheim A
    Biol Aujourdhui; 2017; 211(4):255-264. PubMed ID: 29956652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Type III CRISPR-Cas System: Introduction And Its Application for Genetic Manipulations.
    Liu T; Pan S; Li Y; Peng N; She Q
    Curr Issues Mol Biol; 2018; 26():1-14. PubMed ID: 28879852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-Cas Systems in Streptococci.
    Gong T; Lu M; Zhou X; Zhang A; Tang B; Chen J; Jing M; Li Y
    Curr Issues Mol Biol; 2019; 32():1-38. PubMed ID: 31166168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPRCasdb a successor of CRISPRdb containing CRISPR arrays and cas genes from complete genome sequences, and tools to download and query lists of repeats and spacers.
    Pourcel C; Touchon M; Villeriot N; Vernadet JP; Couvin D; Toffano-Nioche C; Vergnaud G
    Nucleic Acids Res; 2020 Jan; 48(D1):D535-D544. PubMed ID: 31624845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type II anti-CRISPR proteins as a new tool for synthetic biology.
    Zhang Y; Marchisio MA
    RNA Biol; 2021 Aug; 18(8):1085-1098. PubMed ID: 32991234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.